抗高血压药物和口腔癌之间的关联:一种药物向的门德尔随机化研究
Junfeng Guo1,2, Rongxing Liu1, Fangfang Sheng1
1Department of Pharmacy, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Frontiers in pharmacology
|December 13, 2023
概括
抗高血压药物,特别是针对KCNH2的β-腺受体抑制剂,可能会影响口腔癌的风险. 抑制KCNH2似乎可以降低患口腔癌的风险.
科学领域:
- 遗传学 遗传学 是一个
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 新出现的证据表明,抗高血压药物可能在各种癌症中起瘤作用.
- 这些药物对口腔癌风险的具体影响尚不清楚.
研究的目的:
- 调查抗高血压药物使用与口腔癌风险之间的潜在因果关系.
- 评估血压相关遗传变异对口腔癌发展的影响.
主要方法:
- 采用双样本的门德尔随机化 (MR) 方法.
- 利用遗传工具,包括药物向基因的表达量化特征位点 (eQTL) 和全基因组关联研究 (GWAS) 变体.
- 应用逆变量加权MR (IVW-MR) 和基于总结数据的MR (SMR) 分析.
主要成果:
- IVW-MR表明KCNH2介导的血压与口腔癌风险之间存在正相关性 (OR = 1.197).
- SMR分析显示,较高的KCNH2表达 (由β-上腺素受体抑制剂向) 与增加的口腔癌风险相关 (OR = 2.223).
- 没有发现其他关联的一致证据.
结论:
- 这项研究表明,KCNH2抑制与口腔癌风险降低之间存在潜在的因果关系.
- 向KCNH2的β-腺素受体抑制剂可能在预防口腔癌方面发挥作用.
更多相关视频
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.3K
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
4.2K
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
632
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
632
Hazard Ratio
130
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
130
Cancer Prevention
6.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Antihypertensive Drugs: Angiotensin II Receptor Blockers
743
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
743
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
